Therapy for irritable bowel syndrome - Present possibilities and new perspectives

Gastroenterologia Polska

Volumn 11, Issue 6, 2004, Pages 521-527

  Mulak, Agata ^a   Paradowski, Leszek ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Irritable bowel syndrome; Neurotransmitters; Serotonin

Indexed keywords

ALOSETRON; ALVERINE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ANTIDIARRHEAL AGENT; CANNABINOID; CHOLECYSTOKININ; CHOLINERGIC RECEPTOR BLOCKING AGENT; COLESTYRAMINE; CORTICOTROPIN RELEASING FACTOR; DESIPRAMINE; DOXEPIN; HERBACEOUS AGENT; HORMONE; LACTULOSE; LAXATIVE; MEBEVERINE; NEUROTRANSMITTER; OPIATE DERIVATIVE; PEPPERMINT OIL; PROBIOTIC AGENT; SEROTONIN; SEROTONIN AGONIST; SEROTONIN RECEPTOR; SIMVASTATIN; SORBITOL; SPASMOLYTIC AGENT; TACHYKININ; TEGASEROD; TRIMEBUTINE; UNINDEXED DRUG;

ACUPUNCTURE; ALTERNATIVE MEDICINE; BEHAVIOR THERAPY; CHINESE HERB; CLINICAL TRIAL; COGNITIVE THERAPY; CONSTIPATION; DIARRHEA; DIET THERAPY; DRUG EFFICACY; FATIGUE; FEMALE; HEADACHE; HEART INFARCTION; HUMAN; IRRITABLE COLON; ISCHEMIC COLITIS; LIFESTYLE; MALE; NEUROENDOCRINE SYSTEM; ORTHOSTATIC HYPOTENSION; PATHOPHYSIOLOGY; PATIENT EDUCATION; QT PROLONGATION; REVIEW; SIDE EFFECT; SYMPTOMATOLOGY; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 11244278796     PISSN: 12329886     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (76)

1. Drossman D.A., Camilleri M., Mayer E.A., Whitehead W.E.: AGA technical review on irritable bowel syndrome. Gastroenterology, 2002, 123, 2108-2131.
2. Drossman D.A., Corazziari E., Halley N.J., Thompson W.G., Whitehead W.E.: Rome II: a multinational consensus document on functional gastrointestinal disorders. Gut, 1999, 45, suppl. 2, II1-II81.
3. Drossman D.A., Li Z., Andruzzi E., Temple R.D., Talley N.J., Thompson W.G., Whitehead W.E., Janssens J., Funch-Jensen P., Corazziari E.: U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig. Dis. Sci., 1993, 38, 1569-1580.
4. Martin R., Barren J.J., Zacker C.: Irritable bowel syndrome: toward a cost-effective management approach. Am. J. Manag. Care, 2001, 7, suppl. 8, S268-275.
5. Gralnek I.M., Hays R.D., Kilbourne A., Naliboff B., Mayer E.A.: The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology, 2000, 119, 654-660.
6. Akehurst R., Kaltenthaler E.: Treatment of irritable bowel syndrome: a review of randomised controlled trials. Gut, 2001, 48, 272-282.
7. Jailwala J., Imperiale T.F., Kroenke K.: Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials. Ann. Intern. Med., 2000, 133, 136-147.
8. Whitehead W.E., Palsson O.S., Levy R.L., Feld A.D., Von Korff M., Turner M.J.: Psychological symptoms do not predict symptom improvement in standard medical care for irritable bowel syndrome (IBS). Gastroenterology, 2004, 126, suppl. 2, A-88.
9. Patel S.M., Ock S.M., Stason W., Legedz A., Comboy L., Kerr C.E., Jacobson E., Canenguez K., Kelly E., Kaptchuk T., Lembo A.J.: Placebo effect in irritable bowel syndrome (IBS) trials: a meta-analysis. Gastroenterology, 2004, 126, suppl. 2, A-369.
10. Mayer E.A., Naliboff B.D., Chang L.: Basic pathophysiologic mechanisms in irritable bowel syndrome. Dig. Dis. 2001, 19, 212-218.
11. Mayer E.A., Naliboff B.D., Chang L., Coutinho S.V.: Stress and irritable bowel syndrome. Am. J. Physiol. Gastrointest. Liver Physiol., 2001, 280, G519-524.
12. Mulak A., Bonaz B.: Irritable bowel syndrome: a model of the brain-gut interactions. Med. Sci. Monit., 2004, 10, RA52-RA62.
13. Mach T.: The brain-gut axis in irritable bowel syndrome - clinical aspects. Med. Sci. Monit., 2004, 10, RA125-RA131.
14. Garakani A., Win T., Virk S., Gupta S., Kaplan D., Masand P.S.: Comorbidity of irritable bowel syndrome in psychiatric patients: a review. Am. J. Ther., 2003, 10, 61-67.
15. Folks D.G.: The interface of psychiatry and irritable bowel syndrome. Curr. Psychiatry Rep., 2004, 6, 210-215.
16. Silverman D.H., Munakata J.A., Ennes H., Mandelkern M.A., Hoh C.K., Mayer E.A.: Regional cerebral activity in normal and pathological perception of visceral pain. Gastroenterology, 1997, 112, 64-72.
17. Mertz H., Morgan V., Tanner G., Pickens D., Price R., Shyr Y., Kessler R.: Regional cerebral activation in irritable bowel syndrome and control subjects with painful and nonpainful rectal distension. Gastroenterology, 2000, 118, 842-848.
18. Bonaz B., Baciu M., Papillon E., Bost R., Gueddah N., Le Bas J.F., Fournet J., Segebarth C.: Central processing of rectal pain in patients with irritable bowel syndrome: an fMRI study. Am. J. Gastroenterol., 2002, 97, 654-661.
19. Aziz Q., Thompson A.G.: Brain-gut axis in health and disease. Gastroenterology, 1999, 114, 559-578.
20. Crowell M.D.: Role of serotonin in the pathophysiology of the irritable bowel syndrome. Br. J. Pharmacol., 2004, 141, 1285-1293.
21. Barbara G., De Giorgio R., Stanghellini V., Cremon C., Corinaldesi R.: A role for inflammation in irritable bowel syndrome? Gut, 2002, 51, suppl. 1, i41-44.
22. Spiller R.C.: Postinfectious irritable bowel syndrome Gastroenterology, 2003, 124, 1662-1671.
23. Spiller R.C., Jenkins D., Thornley J.P., Hebden J.M., Wright T., Skinner M., Neal K.R.: Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut, 2000, 47, 804-811.
24. Gwee K.A., Collins S.M., Read N.W., Rajnakova A., Deng Y., Graham J.C., McKendrick M.W., Moochhala S.M.: Increased rectal mucosal expression of interleukin 1-beta in recent acquired post-infectious irritable bowel syndrome. Gut, 2003, 53, 523-526.
25. Neal K.R., Hebden J., Spiller R.: Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients. BMJ, 1997, 314, 779-782.
26. Dunlop S.P., Jenkins D., Neal K.R., Spiller R.C.: Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology, 2003, 125, 1651-1659.
27. American Gastroenterological Association Medical Position Statement: Irritable Bowel Syndrome (document approved by the Clinical Practice Committee and the AGA Governing Board). Gastroenterology, 2002, 123, 2105-2107.
28. Camilleri M., Heading R.C., Thompson W.G.: Consensus report: clinical perspectives, mechanisms, diagnosis and management of irritable bowel syndrome. Aliment. Pharmacol. Ther., 2002, 16, 1407-1430.
29. Paterson W.G., Thompson W.G., Vanner S.J., Faloon T.R., Rosser W.W., Birtwhistle R.W., Morse J.L., Touzel T.A.: Recommendations for the management of irritable bowel syndrome in family practice. IBS Consensus Conference Participants. CMAJ, 1999, 161, 154-160.
30. Thompson W.G.: Review article: the treatment of irritable bowel syndrome. Aliment. Pharmacol. Ther., 2002, 16, 1395-1406.
31. Drossman D.A.: Review article: an integrated approach to the irritable bowel syndrome. Aliment. Pharmacol. Ther., 1999, 13, suppl. 2, 3-14.
32. Thompson W.G., Hungin A.P., Neri M., Holtmann G., Sofos S., Delvaux M., Caballero-Plasencia A.: The management of irritable bowel syndrome: a European, primary and secondary care collaboration. Eur. J. Gastroenterol. Hepatol., 2001, 13, 933-939.
33. Dapoigny M., Stockbrugger R.W., Azpiroz R, Collins S., Coremans G., Muller-Lissner S., Oberndorff A., Pace F., Smout A., Vatn M., Whorwell P.: Role of alimentation in irritable bowel syndrome. Digestion, 2003, 67, 225-233.
34. Bijkerk C.J., Muris J.W., Knottnerus J.A., Hoes A.W., de Wit N.J.: Systematic review: the role of different types of fibre in the treatment of irritable bowel syndrome. Aliment. Pharmacol. Ther., 2004, 19, 245-251.
35. Shufflebotham J., Hood S., Potokar J., Probert C.: Tryptophan depletion study in irritable bowel syndrome (IBS). Gastroenterology, 2004, 126, suppl. 2, A-372.
36. Clouse R.E.: Antidepressants for irritable bowel syndrome. Gut, 2003, 52, 598-599.
37. American College of Gastroenterology Functional Gastrointestinal Disorders Task Force. Evidence-based position statement on the management of irritable bowel syndrome in North America. Am. J. Gastroneterol., 2002, 97, suppl. 11, S1-S5.
38. Talley N.J.: Drug therapy options for patients with irritable bowel syndrome. Am. J. Manag. Care, 2001, 7, suppl. 8, S261-267.
39. Talley N.J.: Evaluation of drug treatment in irritable bowel syndrome. Br. J. Clin. Pharmacol., 2003, 56, 362-369.
40. Olden K.W.: Irritable bowel syndrome: an overview of diagnosis and pharmacologic treatment. Cleve. Clin. J. Med., 2003, 70, suppl. 2, S3-7.
41. Alosetron (Lotronex) revisited. Med. Lett. Drugs Ther., 2002, 44, 67-68.
42. Camilleri M., Atanasova E., Carlson P.J., Ahmad U., Kim H.J., Viramontes B.E., McKinzie S., Urrutia R.: Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome. Gastroenterology, 2002, 123, 425-432.
43. Whorwell P., Ruegg P., Earnest D., Dunger-Baldauf C.: Tegaserod significantly improves bloating in female irritable bowel syndrome. Gastroenterology, 2004, 126, suppl. 2, A-643.
44. Busti A.J., Murillo J.R., Cryer B.: Tegaserod-induced myocardial infarction: case report and hypothesis. Pharmacotherapy, 2004, 24, 526-531.
45. Pfannkuche H.J., Buhl T., Gamse R.: The properties of new prokinetically active drug, SDZ HTF 919. Neurogastroenterol. Motility, 1995, 7, 280.
46. Talley N.J.: New drug classes. Neuroenteric modulators for the irritable bowel syndrome. Lancet, 2001, 358, 2061-2068.
47. Scarpignato C., Pelosini I.: Management of irritable bowel syndrome: novel approaches to the pharmacology of gut motility. Can. J. Gastroenterol., 1999, 13, suppl. A, 50A-65A.
48. Talley N.J.: Pharmacologic therapy for the irritable bowel syndrome. Am. J. Gastroenterol., 2003, 98, 750-758.
49. De Ponti F., Tonini M.: Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs, 2001, 61, 317-332.
50. Moro E., Crema F., De Ponti R, Frigo G.: Triptans and gastric accommodation: pharmacological and therapeutic aspects. Dig. Liver Dis., 2004, 36, 85-92.
51. Hunt R.H., Tougas G.: Evolving concepts in functional gastrointestinal disorders: promising directions for novel pharmaceutical treatments. Best. Pract. Res. Clin. Gastroenterol., 2002, 16, 869-883.
52. Callahan M.J.: Irritable bowel syndrome neuropharmacology. A review of approved and investigational compounds. J. Clin. Gastroenterol., 2002, 35, suppl. 1, S58-67.
53. Camilleri M.: Treating irritable bowel syndrome: overview, perspective and future therapies. Br. J. Pharmacol., 2004, 141, 1237-1248.
54. Bonnafous C., Bueno L., Griffin P.H., Schneier H., Rovati L.C., D'Amato M.: Influence of dexloxiglumide on visceromotor and pain response induced by rectal distension in rats. Gastroenterology, 2002, 122, A-527.
55. Hawkes N.D., Rhodes J., Evans B.K., Rhodes P., Hawthorne A.B., Thomas G.A.: Naloxone treatment for irritable bowel syndrome - a randomized controlled trial with an oral formulation. Aliment. Pharmacol. Ther., 2002, 16, 1649-1654.
56. Karviv R., Tiomny E., Grenshpon R., Waisman G., Halpern Z.: Low-dose naltrexone for the treatment of irritable bowel syndrome. Am. J. Gastroenterol., 2003, 98, A-268.
57. Hornby P.J., Prouty S.M.: Involvement of cannabinoid receptors in gut motility and visceral perception. Br. J. Pharmacol., 2004, 141, 1335-1345.
58. Hasler W.L., Soudah H.C., Owyang C.: Somatostatin analog inhibits afferent response to rectal distention in diarrhea-predominant irritable bowel patients. Pharmacol. Exp. Ther., 1994, 268, 1206-1211.
59. Mathias J.R., Clench M.H., Abell T.L., Koch K.L., Lehman G., Robinson M., Rothstein R., Snape W.J.: Effect of leuprolide acetate in treatment of abdominal pain and nausea in premenopausal women with functional bowel disease: a double-blind, placebo-controlled, randomized study. Dig. Dis. Sci., 1998, 43, 1347-1355.
60. Tache Y., Martinez V., Wang L., Million M.: CRF1 receptor signaling pathways are involved in stress-related alterations of colonic function and viscerosensitivity: implications for irritable bowel syndrome. Br. J. Pharmacol., 2004, 141, 1321-1330.
61. Chial H.J., Camilleri M., Ferber I., Delgado-Aros S., Burton D., Mc-Kinzie S., Zinsmeister A.R.: Effects of venlafaxine, buspirone, and placebo on colonic sensor/motor functions in healthy humans. Clin. Gastroenterol. Hepatol., 2003, 1, 211-218.
62. Dunlop S.P., Jenkins D., Neal K.R., Naesdal J., Borgaonker M., Collins S.M., Spiller R.C.: Randomized, double-blind, placebo-controlled trial of prednisolone in post-infectious irritable bowel syndrome. Aliment. Pharmacol. Ther., 2003, 18, 77-84.
63. Barbara G., Stanghellini V., De Giorgio R., Cremon C., Cottrell G.S., Santini D., Pasquinelli G., Morselli-Labate A.M., Grady E.F., Bunnett N.W., Collins S.M., Corinaldesi R.: Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology, 2004, 126, 693-702.
64. Mendall MA., Kumar D.: Antibiotic use, childhood affluence and irritable bowel syndrome (IBS). Eur. J. Gastroenterol. Hepatol., 1998, 10, 59-62.
65. Pimentel M., Chow E.J., Lin H.C.: Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am. J. Gastroenterol., 2000, 95, 3503-3506.
66. Pimentel M., Chow E.J., Lin H.C.: Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome, a double-blind, randomized, placebo-controlled study. Am. J. Gastroenterol., 2003, 98, 412-419.
67. Niedzielin K., Kordecki H., Birksnfeld B.: A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. Eur. J. Gastroenterol. Hepatol., 2001, 13, 1143-1147.
68. Quigley E., O'Mahony L., McCarthy J., Kelly P., Collins J.K., Shanahan R, O'Sullivan G., Kiely B.: Probiotics for the irritable bowel syndrome (IBS): a randomized, double-blind, placebo-controlled comparison of lactobacillus and bifidobacterium strains. Gastroenterology, 2002, 122, A-59.
69. Talley N.J., Owen B.K., Boyce P., Paterson K.: Psychological treatments for irritable bowel syndrome: a critique of controlled treatment trials. Am. J. Gastroenterol., 1996, 91, 277-283.
70. Boyce P.M., Talley N.J., Balaam B., Koloski N.A., Truman G.: A randomized controlled trial of cognitive behaviour therapy, relaxation training, and routine clinical care for the irritable bowel syndrome. Am. J. Gastroenterol., 2003, 98, 2209-2218.
71. Gonsalkorale W.M., Miller V., Afzal A., Whorwell P.J.: Long term benefits of hypnotherapy for irritable bowel syndrome. Gut, 2003, 52, 1623-1629.
72. Simren M., Ringstrom G., Bjornsson E.S., Abrahamsson H.: Treatment with hypnotherapy reduces the sensory and motor component of the gastrocolonic response in irritable bowel syndrome. Psychosom. Med., 2004, 66, 233-238.
73. Chitkara D.K., Cremonini F., Talley N.J.: Psychotherapy and paroxetine: cost effective for severe IBS, or a waste of resources. Gastroenterology, 2003, 125, 1554-1555.
74. Bensoussan A., Talley N.J., Hing M., Menzies R., Quo A., Ngu M.: Treatment of irritable bowel syndrome with Chinese herbal medicine: a randomized controlled trial. JAMA, 1998, 280, 1585-1589.
75. Pittler M.H., Ernst E.: Peppermint oil for irritable bowel syndrome: a critical review and metaanalysis. Am. J. Gastroenetrol., 1998, 93, 1131-1135.
76. Pireman Z., Segal A., Kopelman Y., Sternberg A., Carasso R.: Acupuncture treatment for irritable bowel syndrome: A double-blind controlled study. Digestion, 2001, 64, 100-103.